These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 10204633)

  • 1. Antibiotic resistance and therapeutic options in lower respiratory tract infections.
    Bouza E
    Int J Antimicrob Agents; 1999 Mar; 11 Suppl 1():S3-6; discussion S31-2. PubMed ID: 10204633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
    Pfaller MA; Ehrhardt AF; Jones RN
    Am J Med; 2001 Dec; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of antimicrobial resistance in community-acquired pulmonary pathogens.
    Cunha BA; Shea KW
    Semin Respir Infect; 1998 Mar; 13(1):43-53. PubMed ID: 9543475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [beta-lactam-antibiotics in the treatment of community-acquired respiratory tract infections with penicillin-resistant pneumococci].
    Brauers J; Ewig S; Kresken M
    Pneumologie; 2002 Oct; 56(10):605-9. PubMed ID: 12375222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae.
    Appelbaum PC
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S29-34. PubMed ID: 10984325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
    Feldman C
    J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Streptococcus pneumoniae: does antimicrobial resistance matter?
    Lynch JP; Zhanel GG
    Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial resistance in Streptococcus pneumoniae: implications for patients with community-acquired pneumonia.
    Chenoweth CE; Saint S; Martinez F; Lynch JP; Fendrick AM
    Mayo Clin Proc; 2000 Nov; 75(11):1161-8. PubMed ID: 11075746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparative development of elevated resistance to macrolides in community-acquired pneumonia caused by Streptococcus pneumoniae.
    Yayan J
    Drug Des Devel Ther; 2014; 8():1733-43. PubMed ID: 25336917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia.
    Aspa J; Rajas O; de Castro FR
    Expert Opin Pharmacother; 2008 Feb; 9(2):229-41. PubMed ID: 18201146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Community-acquired Streptococcus viridans pneumonia in a healthy child.
    Liaw FY; Wang CC; Chang YW; Chen SJ
    Indian Pediatr; 2012 Apr; 49(4):324-6. PubMed ID: 22565080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrolides are ideal for empiric therapy of community-acquired pneumonia in the immunocompetent host.
    Vergis EN; Yu VL
    Semin Respir Infect; 1997 Dec; 12(4):322-8. PubMed ID: 9436959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D
    J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of new antibacterial therapies in at-risk populations.
    Lorenz J
    J Infect; 2002 Feb; 44 Suppl A():25-30. PubMed ID: 12150492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia.
    File TM
    Clin Infect Dis; 2004 Sep; 39 Suppl 3():S159-64. PubMed ID: 15546111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Penicillin and macrolide resistance in pneumococcal pneumonia: does in vitro resistance affect clinical outcomes?
    Rothermel CD
    Clin Infect Dis; 2004 May; 38 Suppl 4():S346-9. PubMed ID: 15127368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000).
    Kohno S; Hoban D;
    J Chemother; 2003 Aug; 15(4):335-41. PubMed ID: 12962361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empirical therapy of community-acquired pneumonia: macrolides are not ideal choices.
    Bartlett JG
    Semin Respir Infect; 1997 Dec; 12(4):329-33. PubMed ID: 9436960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy.
    Charles PG; Whitby M; Fuller AJ; Stirling R; Wright AA; Korman TM; Holmes PW; Christiansen KJ; Waterer GW; Pierce RJ; Mayall BC; Armstrong JG; Catton MG; Nimmo GR; Johnson B; Hooy M; Grayson ML;
    Clin Infect Dis; 2008 May; 46(10):1513-21. PubMed ID: 18419484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.